SynthesisMedicine2018
Relation of metabolic syndrome and its components with risk of diabetic retinopathy: A meta-analysis of observational studies.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- QiMing granules for diabetic retinopathy: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2024Pooled it
- Eye disease and mortality, cognition, disease, and modifiable risk factors: an umbrella review of meta-analyses of observational studies.Eye (London, England) · 2022Pooled it
- Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies.Journal of diabetes investigation · 2021Pooled it
- Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations.BMC cardiovascular disorders · 2021Pooled it
- Trends of metabolic syndrome among Iranian patients with diabetes and its association with cardiovascular disease and diabetes complications: a nationwide study of the National Program for Prevention and Control of Diabetes.BMC endocrine disorders · 2025Article
- The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity.Diabetologia · 2023Article
- Article
- The Prevalence and Determinants of Cognitive Deficits and Traditional Diabetic Complications in the Severely Obese.Diabetes care · 2020Article
- Ocular findings in metabolic syndrome: a review.Porto biomedical journalReview
- Demographic and Metabolic Risk Factors Associated with Development of Diabetic Macular Edema among Persons with Diabetes Mellitus.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging studies have reported the effects of metabolic syndrome (MetS) and its components on risk of diabetic retinopathy (DR), but the results remain controversial. Therefore, we performed a meta-analysis to evaluate the relationship between MetS and risk of DR.A meta-analysis of observational studies.Studies were searched from PubMed, Cochrane Library, and Elsevier databases from the start of the database up until November 30, 2017. Adjusted odds ratios (ORs) and its corresponding 95% confidence intervals (CIs) were extracted and pooled by using a random effects model.A total of 12 observational studies were included in this meta-analysis. When the MetS as a full syndrome, MetS was not associated with increased risks of type 1 (OR = 1.47, 95% CI 0.67-3.24; P = .34) or type 2 (OR = 1.34, 95% CI 0.91-1.98; P = .14) DR. In addition, none of single component of MetS was associated with the risk of DR, including body mass index/waist circumference (BMI/WC) (OR = 0.92, 95% CI 0.75-1.13; P = .41), blood pressure (OR = 1.37, 95% CI 0.96-1.95; P = .08), high density lipoprotein (OR = 0.97, 95% CI 0.93-1.01; P = .19), and triglyceride (OR = 0.85, 95% CI 0.63-1.15; P = .29). In the sensitivity analysis, the pooled OR values were not changed after we removed the included studies one by one.Based on recent published data, neither MetS nor its components are associated with an increased risk of DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.